REGN

Regeneron Pharmaceuticals 주식 (NASDAQ: REGN)

에 대한 최신 뉴스 Regeneron Pharmaceuticals (NASDAQ:REGN) 주식

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Eli Lilly and Co.

Equities

Government

News

Markets

ABBV

AMGN

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

도널드 트럼프 대통령은 수요일(9일) 상호관세를 90일 동안 일시 중단했지만, 나중에 집무실에서 기자들과의 대화에서 제약 회사들이 관세에 직면할 것이라고 확인했다. 

트럼프의 의약품 관세 확인...일라이릴리·애브비·리제네론·브리스톨 등 제약주 급락

Stethoscope,Laying,On,Medicine,White,Pills,Money,With,Rx,Prescription

Analyst Color

Biotech

Large Cap

Health Care

Analyst Ratings

Movers

Trading Ideas

General

ARGX

RHHBY

UCBJF

UCBJY

도널드 트럼프 대통령은 화요일(8일) 외국 의약품에 대한 &#34;주요 관세&#34; 계획을 공개했다.트럼프 대통령은 전국공화당의회위원회(NRCC) 만찬에서 이렇게 말했다. &#34;우리는 곧 의약품에 대한 주요 관세를 발표할 것이다...관세 소식을 들으면 회사들은 중국을 떠날 것이다...대부분 제품이 미국에서 판매되기 때문이다.&#34;

트럼프의 의약품 관세 계획...뱅크오브아메리카에서 제시한 타임라인은?

Healthcare,,Opioid,Epidemic,And,Drug,Abuse,Concept,With,The,Map

ELAN

IDXX

PRGO

TEVA

VTRS

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다. 강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다. 

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

Regnum Corp

Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Neutral and lowers the price target from $759 to $652.

Price Target

Baird Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $652

Truist Securities analyst Srikripa Devarakonda maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and lowers the price target from $1004 to $975.

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $975

Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supply bulk drug products of Regeneron&#8217;s commercial biologic medicines at their Holly Springs, <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">North Carolina, campus</a>.
Regeneron, already one of the world&#8217;s largest biologics manufacturers, will nearly double its U.S. large-scale manufacturing capacity by accessing Fujifilm&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44916999/regeneron-announces-new-investment-in-manufacturing-of-its-industry-leading-biologic-medicines" rel="noreferrer noopener">new biopharmaceutical facility</a>.
With technology transfer beginning immediately and a 10-year term, the total investment is estimated to exceed $3 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44870253/fda-accepts-priority-review-of-regenerons-flagship-drug-eylea-hd-for-expanded-use" rel="noreferrer noopener">FDA Sets The Countdown: Regeneron&#8217;s Eylea HD Could Be Headed For Major Expansion</a>
&#8220;Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories&#8230;&#8221; said Leonard Schleifer, Board co-Chair, president and CEO of Regeneron.
&#8220;FUJIFILM Diosynth Biotechnologies will be bringing additional capacity online in 2025, 2026 and beyond as it completes the current $7 billion of expansion projects underway in both Europe and United States,&#8221; &nbsp;said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio-CDMO Division,<a href="https://www.benzinga.com/pressreleases/25/04/b44917015/fujifilm-diosynth-biotechnologies-and-regeneron-sign-a-10-year-u-s-manufacturing-agreement-valued-" target="_blank" rel="noreferrer noopener"> FUJIFILM Corporation, Japan</a>.
Regeneron continues to invest heavily in its New York State operations. An approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing, and support facilities.
In addition, the company is constructing a brand new fill/finish manufacturing facility in Rensselaer, New York. It has acquired an over 1 million-square-foot property in Saratoga Springs, New York, for production support activities and, potentially, additional manufacturing capacity.
Regeneron has added more than 7,000 jobs in the past five years, most of which are high-paying R&amp;D and manufacturing jobs based in the U.S.
Regeneron&#8217;s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing are expected to total more than $7 billion.
On Friday, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Regeneron&#8217;s Eylea (aflibercept) Injection 8 mg <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44886470/regeneron-provides-update-on-eylea-hd-aflibercept-injection-8-mg-supplemental-biologics-license-ap" rel="noreferrer noopener">across all approved indications</a>.
The CRL did not identify any issues with the safety or efficacy of Eylea HD in its approved indications and dosing regimens. The FDA did not agree with Regeneron&#8217;s proposal to add additional extended dosing intervals (greater than every 16 weeks, which is the maximum dosing interval currently indicated in the label). Regeneron is evaluating the FDA&#8217;s decision.
On Friday, the FDA approved Regeneron and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) partnered Dupixent&nbsp;(dupilumab) for adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44884755/dupixent-dupilumab-approved-in-the-u-s-as-the-first-new-targeted-therapy-in-over-a-decade-for-chro" rel="noreferrer noopener">antihistamine treatment</a>.
Price Action: REGN stock is up 4.2% at $585.25 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44922218/lockheed-martin-posts-strong-q1-says-maintained-2025-guidance-doesnt-include-tariff-impact" target="_blank" rel="noreferrer noopener">Lockheed Martin Does Not Alter Annual Outlook To Price Tariff Impact Yet Amid Recent CFO Change</a></li>
</ul>
Photo: Shutterstock

Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal

Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and lowers the price target from $1152 to $850.

Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $850

Cantor Fitzgerald analyst Carter Gould assumes Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight rating and announces Price Target of $695.

Initiation

Cantor Fitzgerald Assumes Regeneron Pharmaceuticals at Overweight, Announces Price Target of $695

FUJIFILM Diosynth Biotechnologies Ink 10-Year Manufacturing Supply Agreement Worth $3B With Regeneron Pharmaceuticals

Reported Friday, Regeneron Receives FDA Complete Response On EYLEA HD Application, No Safety Or Efficacy Issues Identified

Regeneron Pharmaceuticals And Sanofi Announce FDA Approval of Dupixent For Chronic Spontaneous Urticaria in Adults and Adolescents

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) supplemental Biologics License Application (sBLA) for Eylea HD <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">(aflibercept) Injection 8 mg</a>.
The sBLA seeks approval for Eylea HD for macular edema following retinal vein occlusion (RVO) and broadening the dosing schedule to include every 4-week (monthly) dosing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44859817/eylea-hd-aflibercept-injection-8-mg-sbla-accepted-for-fda-priority-review-for-both-the-treatment-o" rel="noreferrer noopener">across approved indications</a>.
The FDA target action date is&nbsp;August 19, 2025,&nbsp;following the use of a Priority Review voucher.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44652995/vertex-alnylam-best-positioned-as-biopharma-braces-for-tariff-impact-goldman-sachs-analyst-flags-regeneron-biogen-risks" rel="noreferrer noopener">Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks</a>
Data from the Eylea HD clinical program, including the Phase 3 QUASAR trial investigating Eylea HD in RVO, support the sBLA.
As previously&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=lIY80eDymaJZTWtLLbkBCRJgLnw2xcuCCdcj05NnO7aQugCej2rSB-zxhlnSmVvIJtcp9WlMpwFT7g_ixbuUN_6RxF6YOpU3cekCfcfehEuYFoUswmcHNzGl7qhrlOJZcZAltDicvv2wm386xTGOL0rcZwEQtPkSCfofA-sVLXVcoWFLTd20X7qrroJsJlKLtw6Q0ijcy5JR997n5OTAAbcjYhY8cPLAy5AzmGBZOHU=&amp;tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">presented</a>, QUASAR met its primary endpoint at 36 weeks. Eylea HD patients were dosed every 8 weeks (after 3 or 5 monthly doses), achieving non-inferior visual acuity gains compared to those receiving Eylea&nbsp;(aflibercept) Injection 2 mg dosed every 4 weeks.
All anti-VEGF therapies approved to treat RVO, including Eylea, are indicated for monthly dosing.
In QUASAR, the safety profile of EYLEA HD (n=591) was similar to Eylea (n=301). It remained generally consistent with the known safety profile of Eylea HD in its pivotal trials for approved indications and with the <a target="_blank" href="https://www.benzinga.com/24/12/42536756/regenerons-best-selling-eye-drug-eyleas-higher-dose-formulation-meets-primary-goal-in-another-form-of-retinal-disease-study" rel="noreferrer noopener">established safety profile of Eylea</a>.
Increased ocular pressure (5%) was the only ocular treatment-emergent adverse event that occurred in ≥5% of all Eylea HD patients, compared to 1.7% of Eylea patients.
There was one case each of endophthalmitis and retinal vasculitis in all Eylea HD patients, compared to two cases of endophthalmitis and no cases of retinal vasculitis in Eylea patients.
No cases of occlusive retinal vasculitis were reported. The rate of intraocular inflammation was 0.5% for Eylea HD and 1.3% for Eylea.
The safety and efficacy of Eylea HD for RVO and monthly dosing in approved indications have not been evaluated by any regulatory authority.
B of A Securities maintains Regeneron Pharmaceuticals with an Underperform and lowers the price <a target="_blank" href="https://www.benzinga.com/quote/REGN/analyst-ratings" rel="noreferrer noopener">target from $575 to $547</a>.
Price Action: REGN stock is up 1.3% at $556.48 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/04/44863342/retail-giant-costco-raises-dividend-by-12" target="_blank" rel="noreferrer noopener">Retail Giant Costco Raises Dividend By 12%</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% decrease, the current average has fallen from the previous average price target of $912.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1744891323_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Regeneron Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tim Anderson &#x7C;B of A Securities &#x7C;Lowers &#x7C;Underperform &#x7C; $547.00&#x7C;$575.00 &#x7C; 
&#x7C;Salveen Richter &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $917.00&#x7C;$1019.00 &#x7C; 
&#x7C;Chris Schott &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $1000.00&#x7C;$1100.00 &#x7C; 
&#x7C;Brian Skorney &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $759.00&#x7C;$940.00 &#x7C; 
&#x7C;David Risinger &#x7C;Leerink Partners &#x7C;Raises &#x7C;Outperform &#x7C; $834.00&#x7C;$762.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $750.00&#x7C;$795.00 &#x7C; 
&#x7C;Christopher Raymond &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $1013.00&#x7C;$1195.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Regeneron Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Regeneron Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/REGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Regeneron Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Regeneron Pharmaceuticals</h2>
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
<h3>Regeneron Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Regeneron Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.33% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Regeneron Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 24.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts

B of A Securities analyst Tim Anderson maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Underperform and lowers the price target from $575 to $547.

B of A Securities Maintains Underperform on Regeneron Pharmaceuticals, Lowers Price Target to $547

FDA Accepts Regeneron's EYLEA HD Injection 8 mg sBLA For Priority Review For Treatment Of Macular Edema Following Retinal Vein Occlusion And For Monthly Dosing In Approved Indications

US President Donald Trump issued a multi-part executive order on Tuesday to lower drug prices and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">reduce Medicare costs</a>.
Within 60 days, the Secretary of Health and Human Services is instructed to seek guidance for the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028.
<ul>
<li>This guidance will focus on greater transparency, selecting high-cost drugs, and safeguarding pharmaceutical innovation.</li>
<li>Additionally, the administration seeks to eliminate a key disparity in how Medicare treats small-molecule drugs compared to biologics, discouraging investment in more affordable treatments.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
The White House is also <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/" rel="noreferrer noopener">targeting</a> the rising costs seniors face under Medicare. A new payment model will be tested within a year to obtain better value for high-cost drugs and biologicals, including those not subject to price negotiations.
Further, the administration wants to align Medicare payments with actual hospital acquisition costs through a national survey, with potential reimbursement adjustments following the results.
To reform Medicaid drug pricing, the administration will develop recommendations linking drug payments to their value and ensuring accurate rebate payments from manufacturers. The initiative also aims to assist states in managing spending while promoting innovation in Medicaid reimbursement.
Affordability for life-saving medications is another key focus: Community health centers will be required to offer insulin and epinephrine at or below discounted 340B prices to low-income individuals with high out-of-pocket costs or no insurance, with compliance tied to eligibility for future federal grants..
To address price manipulation in the supply chain, the administration calls for reevaluating middlemen roles, such as pharmacy benefit managers, and seeking transparency in their compensation structures. Within 90 days, recommendations to promote a more efficient pharmaceutical market are expected.
Other planned reforms include accelerating FDA approvals for generics and over-the-counter conversions, streamlining the drug importation program, and ensuring Medicare payments do not incentivize hospital-based care over less costly physician offices.
Lastly, federal agencies will investigate anti-competitive practices by drug manufacturers, with public listening sessions and policy recommendations expected within six months.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44826592/netflix-wants-to-be-the-next-1-trillion-company-analyst-highlights-growth-path" target="_blank" rel="noreferrer noopener">Netflix Wants To Be The Next $1 Trillion Company, Analyst Highlights Growth Path</a></li>
</ul>
Photo by Aria Armoko via Shutterstock

Regulations

BIIB

BMRN

VRTX

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction

<a target="_blank" href="https://www.benzinga.com/quote/SNY" rel="noreferrer noopener">Sanofi SA</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Tuesday shared progress from its mid- to <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">late-stage respiratory pipeline</a>.
The French drug maker <a href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-15-05-00-00-3061368" target="_blank" rel="noreferrer noopener">reported</a> preliminary results from the TIDE-Asthma phase 2 study of amlitelimab and its efficacy in heterogeneous inflammatory asthma. Here&#8217;s what we know: 
<ul>
<li>The primary endpoint of the annualized exacerbation rate at week 48 was not met at the highest dose level, leading to nominal significance at the medium and low doses.</li>
<li>Treatment with amlitelimab led to nominally significant and clinically meaningful reductions in asthma exacerbations at the medium dose tested and a numerically greater reduction in exacerbations at the high dose at week 60.</li>
<li>A nominally significant and clinically meaningful improvement in secondary endpoints of lung function and asthma control was evident.</li>
<li>In a patient subgroup, amlitelimab showed nominally significant and clinically meaningful improvements in exacerbations (with a reduction of more than 70%), lung function, and asthma control at week 60.</li>
<li>The phase 3 program is currently being planned.</li>
<li>In the TIDE-Asthma study, patients were treated every four weeks for the first 24 weeks and every 12 weeks for the remaining 36 weeks. Amlitelimab&#8217;s durable efficacy through 60 weeks of treatment supports a quarterly maintenance dosing schedule.</li>
<li>The safety profile was consistent with previous studies across indications, with no new safety signals identified throughout the 60-week treatment period.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
Separately, Sanofi said lunsekimig is being explored in a broad population of asthma patients, regardless of their inflammation and severity status.
<ul>
<li>The readout of the AIRCULES phase 2 study in moderate to severe asthma is anticipated in 2026 </li>
<li>The AIRLYMPUS phase 2 study in high-risk asthma was initiated in Q4 2024.</li>
<li>The readout of the phase 2 study in patients with chronic rhinosinusitis with nasal polyps is anticipated in 2026.</li>
<li>A phase 2/3 study in chronic obstructive pulmonary disease (COPD) will begin in 2025.</li>
</ul>
In partnership with Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), two phase 3 studies were initiated so far this year.
Itepekimab is currently being explored in COPD in two phase 3 studies, AERIFY-1 and AERIFY-2, with the readout anticipated in H2 2025, and in one phase 2 study, AERIFY-3, with the readout anticipated in H2 2025.
Finally, itepekimab is being explored in a phase 2 study in bronchiectasis, with the readout anticipated in 2026.
In May 2024, Sanofi <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-05-22-17-15-00-2886776?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">reported</a> results from the Phase 2 study of oral&nbsp;rilzabrutinib&nbsp;in adult patients with uncontrolled moderate-to-severe asthma.
Two doses of&nbsp;rilzabrutinib, 800 mg daily and 1200 mg <a target="_blank" href="https://www.benzinga.com/news/24/05/38970663/first-advanced-oral-treatment-for-asthma-sanofis-investigational-drug-shows-potential" rel="noreferrer noopener">daily, were studied</a>.
The data showed that treatment with oral&nbsp;rilzabrutinib&nbsp;at both high and low doses led to a numerical reduction in loss of asthma control (LOAC) events (the primary endpoint) and improvements in symptoms in adult patients with uncontrolled moderate-to-severe asthma.&nbsp;
Price Action: SNY stock is down 1.33% at $51.15 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/04/44819954/apple-plans-on-device-ai-data-analysis-to-boost-privacy-catch-up-in-ai-race" target="_blank" rel="noreferrer noopener">Apple Plans On-Device AI Data Analysis To Boost Privacy, Catch Up In AI Race</a></li>
</ul>
Image: Shutterstock

Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study

Goldman Sachs analyst Salveen Richter maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and lowers the price target from $1019 to $917.

Goldman Sachs Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $917

Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would face tariffs.
What Happened: The rally in pharma stocks was short-lived after the stocks reversed course on Thursday. When a reporter asked President Trump if he would go ahead and levy tariff duties on pharmaceutical stocks, he said, &#8220;Yeah, well, I will be because we want them coming back.&#8221;
&#8220;You know, we realized during COVID-19 that we don&#8217;t make our drugs and our pharmaceuticals in this country. So, I realized that, and it was a big realization,&#8221; he added.
Citing the emergency during COVID-19, he stated that he wanted the pharma companies to produce drugs in the U.S.
&#8220;We had to go to China to get drugs, we had to go to other places, we don&#8217;t make it. That&#8217;s because we let them leave, and now if they want to come back, we&#8217;re going to put tariffs on the pharmaceutical companies, and they&#8217;re going to all want to come back,&#8221; Trump said.
The pharma stocks tumbled on Thursday after Trump&#8217;s confirmation of tariffs.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>Thursday&#8217;s Performance</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-4.35%</td>
<td>-7.35%</td>
<td>-5.09%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.14%</td>
<td>-2.92%</td>
<td>3.99%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-6.10%</td>
<td>-11.15%</td>
<td>2.73%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-5.26%</td>
<td>-23.60%</td>
<td>-40.63%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.87%</td>
<td>-18.87%</td>
<td>-18.03%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.66%</td>
<td>10.36%</td>
<td>47.71%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-5.32%</td>
<td>-21.80%</td>
<td>-38.53%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>-3.33%</td>
<td>8.54%</td>
<td>4.23%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>-1.51%</td>
<td>3.24%</td>
<td>-0.07%</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/04/44755181/pentagon-slashes-5-1-billion-in-accenture-deloitte-booz-allen-contracts-thats-a-lot-of-consulting">Pentagon Slashes $5.1 Billion In Accenture, Deloitte, Booz Allen Contracts: &#8216;That&#8217;s A Lot Of Consulting&#8217;</a>
Why It Matters: Despite a 90-day pause on reciprocal tariffs, base global tariffs of 10% and China tariffs of 125%, along with sector-specific tariffs of 25% on steel and aluminum, auto, and auto parts remain in place. Adding to it, the President hinted that he could soon announce tariffs on pharmaceutical companies.
Here are some of the pharmaceutical industry-linked exchange-traded funds that could be impacted.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-7.02%</td>
<td>-7.51%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-7.04%</td>
<td>-6.08%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-10.13%</td>
<td>-4.37%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-14.05%</td>
<td>-11.45%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>2.88%</td>
<td>0.35%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-11.54%</td>
<td>-10.18%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-41.35%</td>
<td>-43.86%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: After Thursday&#8217;s fall, following Wednesday&#8217;s rebound, the Nasdaq 100 index was 17.46% lower than its previous high of 22,222.61 points. The S&amp;P 500 index was down 14.31% from its record of 6,147.43 points, and the Dow Jones declined 12.16% from its 52-week high of 45,073.63 points.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended lower on Thursday. The SPY was down 4.38% to $524.58, while the QQQ declined 4.25% to $446.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44728276/spy-qqq-call-volumes-spiked-minutes-before-tariff-pause-announcement-alexandria-ocasio-cortez-demands-disclosure-from-congress-members" target="_blank" rel="noreferrer noopener">SPY, QQQ Call Volumes Spiked Minutes Before Tariff Pause Announcement: Alexandria Ocasio-Cortez Demands Disclosure From Congress Members</a></li>
</ul>
Photo courtesy: Shutterstock

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies

U.S.&nbsp;President Donald Trump, on Tuesday, disclosed plans for a "major tariff" on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">foreign pharmaceuticals</a>.
"We're&nbsp;going to be announcing very&nbsp;shortly a major tariff on&nbsp;pharmaceuticals… when they hear that&nbsp;they will leave China, they&nbsp;will leave other places because… most of their product&nbsp;is sold here," Trump expressed at&nbsp;a National Republican <a target="_blank" href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market" rel="noreferrer noopener">Congressional Committee&nbsp;dinner</a>.
He also told reporters on board his Air Force One plane that "pharma" tariffs would arrive "at a level that you haven't really seen before," saying these would be announced "in the near future," BBC <a target="_blank" href="https://www.bbc.com/news/articles/cedyylj1v32o" rel="noreferrer noopener">report</a> added.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">Trump Tariff Strategy Creates ‘Self-Inflicted Market Debacle': Analyst</a>
When President Trump announced tariffs last week, he excluded pharmaceuticals from the new tariffs, likely a relief for the industry under pressure following his prior comments suggesting a 25% tariff&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">on pharmaceutical imports</a>.&nbsp;
On Wednesday, in a surprise announcement from President Donald Trump, a 90-day pause on tariffs for countries that have not retaliated <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">against U.S. trade measures.</a>
The news ignited a broad risk-on rally, catapulting major indices to multi-month highs and sending volatility plunging.
Trump's latest Truth Social post slammed China for showing "a lack of respect" and declared an immediate 125% tariff hike on Chinese goods.
"At some point, hopefully in the near future, China will realize that the days of ripping off the U.S.A. and other Countries is no longer sustainable or acceptable," he said.
He praised the over 75 countries that, in his words, "have not, at my strong suggestion, retaliated in any way, shape, or form."
As a reward, those countries would benefit from a temporary 10% reciprocal tariff and a 90-day pause on additional duties.
The biopharma industry has historically been shielded from tariffs, including during Trump's first term.
Although Trump didn't provide many details, his remarks have unsettled buyers, especially those who depend on medicines from India. India provides nearly half of all generic drugs used in the U.S., helping cut billions from healthcare costs.
The U.S. is a major market, buying about a third of India's $13 billion in yearly drug exports.
Indian drug companies warn that if tariffs are added, they'd have to raise prices—which could increase healthcare costs in the U.S.
Even though some companies like Cipla and Dr. Reddy's Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) have factories in the U.S., most say it's too expensive to move production for low-profit generic drugs.
BofA Securities analyst says if the Trump administration plans to impose tariffs on the pharmaceutical industry, it would likely do so through a "Section 232 investigation" under the Trade Expansion Act of 1962 to determine whether importing certain goods threatens national security.
The typical timeline for a Section 232 investigation is about a year. If the same timeline applied here, tariffs on drug imports likely wouldn't take effect until late in the year—at the earliest.
It's unclear whether the Section 232 investigation into the drug industry is about to start, but based on recent comments from the administration, it seems possible. However, launching an investigation doesn't guarantee that tariffs will follow.
As the first quarter 2025 earnings season starts soon, analyst Tim Anderson says it will be worth watching whether companies discuss potential tariffs during earnings calls.
That said, any actual earnings impact likely wouldn't show up until sometime after 2025, which could leave investors with more questions than answers.
Wedbush analyst Daniel Ives <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">on Tuesday wrote</a> that "saying we can just make this in the USA" understates how complex the supply chain in Asia really is—and how electronics, chips, semiconductors, hardware, and smartphones have been built for U.S. consumers over the past 30 years."
Shares of major drugmakers such as Gilead Sciences&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Eli Lilly&nbsp;And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), AstraZeneca&nbsp;Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Roche&nbsp;Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Sanofi&nbsp;SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Novartis&nbsp;AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Argenx&nbsp;SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>), UCB&nbsp;SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>), Novo Nordisk&nbsp;A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) fell on Wednesday, only reverse course later after the 90-day tariff pause.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44723376/goldman-sachs-scraps-recession-call-after-trumps-surprise-tariff-pause-as-wall-street-marks-strongest-day-since-2008" target="_blank" rel="noreferrer noopener">Goldman Sachs Scraps Recession Call After Trump's Surprise Tariff Pause As Wall Street Marks Strongest Day Since 2008</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Regeneron Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NYSE">REGN</a>) short percent of float has risen 26.83% since its last report. The company recently reported that it has 3.25 million shares sold short, which is 3.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Regeneron Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744214430_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Regeneron Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Regeneron Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 6.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Regeneron Pharmaceuticals Gaining or Losing Market Support?

Several exemptions exist among President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted" target="_blank" rel="noopener">broad tariffs</a>, which were announced on Wednesday. 
The biopharma industry has historically been shielded from tariffs, including during Trump&#8217;s first term. Given its significant manufacturing presence in Europe, investors had feared global tariffs could disrupt the sector.
Morningstar <a href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" target="_blank" rel="noopener">reports</a> that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the industry $20 billion, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44642463/french-president-macron-suggests-suspension-of-eu-investments-in-us-amid-tariff-turmoil" rel="noreferrer noopener">French President Macron Suggests Suspension Of EU Investments In US Amid Tariff Turmoil, Vows &#8216;More Powerful&#8217; Response</a>
Goldman Sachs expects continued volatility in the biotechnology sector (XBI and S&amp;P 500 are down about 14% and 7% year-to-date, respectively), driven by broader economic <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" rel="noreferrer noopener">uncertainty and unclear healthcare policy</a>.
Analyst Salveen Richter has analyzed geographic exposure and tax rates for individual companies and sees Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) in the strongest position, followed by Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often import ingredients or finished products into the U.S.
Analyst Richter adds that <a target="_blank" href="https://www.benzinga.com/quote/AMGN" rel="noreferrer noopener">Amgen</a>, <a target="_blank" href="https://www.benzinga.com/quote/ALNY" rel="noreferrer noopener">Alnylam</a>, <a target="_blank" href="https://www.benzinga.com/quote/BIIB" rel="noreferrer noopener">Biogen</a>, and <a target="_blank" href="https://www.benzinga.com/quote/REGN" rel="noreferrer noopener">Regeneron</a> are the least exposed to Medicaid risk.
Goldman Sachs said Friday that it&#8217;s been hard to measure the exact impact of potential tariffs on U.S. biopharma due to limited public data on where drugs are made.
Their analysis shows limited manufacturing exposure to Canada, Mexico and China. Pharmaceuticals from Canada and Mexico are also likely exempt under the USMCA trade deal. However, some companies do rely heavily on manufacturing in the EU.
If tariffs are placed on drugs made outside the U.S. and kept in place, they could raise manufacturing costs. Companies often import ingredients or finished products before selling them in the U.S. Some manufacturers are reportedly speeding up shipments from Europe out of concern that tariffs may apply to <a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noopener">those products,</a><a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noreferrer noopener"> too</a>.
Goldman Sachs is also watching for exceptions or phased rollouts, pointing to a similar eight-year grace period in the Biosecure Act.
Still, the analyst writes that biopharma companies are generally resilient due to their high profit margins and globally spread operations.
Companies that produce small-molecule drugs might handle a U.S. manufacturing shift better than those making biologics since small molecules require less complex production.
Senator Ron Wyden has raised concerns about Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) using offshore setups to reduce U.S. taxes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44648087/karman-strikes-90m-deal-for-mti-enhancing-position-in-next-gen-defense-technologies" target="_blank" rel="noreferrer noopener">Karman Strikes $90M Deal For MTI, Enhancing Position In Next-Gen Defense Technologies</a></li>
</ul>
Photo: Shutterstock

ALNY

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1100 to $1000.

JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1000

Earnings

Press Releases

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

Regeneron Announces Investor Conference Presentations

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion

PARIS:SAN

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Baird

Truist Securities

Canaccord Genuity

Cantor Fitzgerald

B of A Securities

Screenshot 2024-09-10 at 8.49.39 PM

MAIA

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

도널드 트럼프 대통령은 수요일(9일) 상호관세를 90일 동안 일시 중단했지만, 나중에 집무실에서 기자들과의 대화에서 제약 회사들이 관세에 직면할 것이라고 확인했다.
무슨 일 있었나: 제약주 랠리는 목요일 시장이 하락세로 전환되면서 단기간에 그쳤다. 한 기자가 트럼프 대통령에게 제약 주식에 관세를 부과할 것이냐는 질문을 하자, 트럼프 대통령은 이렇게 답했다. "그렇게 할 것이다. 왜냐하면 우리는 그들이 다시 돌아오기를 원하기 때문이다.&#8221;
"코로나19를 겪으면서 우리는 미국에서 의약품을 만들지 않는다는 사실을 깨달았다. 그래서 큰 깨달음을 얻었다.&#8221;
트럼프는 코로나19의 비상 사태를 언급하며 제약 회사들이 미국에서 의약품을 생산하기를 원한다고 말했다.
"우리는 약을 구하기 위해 중국으로 가야 했고, 다른 곳으로 가야 했고, 약을 구하지 못했다. 우리가 그들이 떠나도록 내버려 두었기 때문이다&#8230;제약 회사에 관세를 부과할 것이고, 모두 돌아오고 싶어 할 것이다.&#8221;
트럼프의 관세 확정 이후 목요일 제약주는 급락했다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>제약주</td>
<td>목요일 주가 변동</td>
<td>2025년 변동</td>
<td>지난 1년 변동</td>
</tr>
<tr>
<td>일라이 릴리 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-4.35%</td>
<td>-7.35%</td>
<td>-5.09%</td>
</tr>
<tr>
<td>애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.14%</td>
<td>-2.92%</td>
<td>3.99%</td>
</tr>
<tr>
<td>브리스톨 마이어스 스퀴브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-6.10%</td>
<td>-11.15%</td>
<td>2.73%</td>
</tr>
<tr>
<td>리제네론 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-5.26%</td>
<td>-23.60%</td>
<td>-40.63%</td>
</tr>
<tr>
<td>화이자 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.87%</td>
<td>-18.87%</td>
<td>-18.03%</td>
</tr>
<tr>
<td>길리어드 사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.66%</td>
<td>10.36%</td>
<td>47.71%</td>
</tr>
<tr>
<td>머크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-5.32%</td>
<td>-21.80%</td>
<td>-38.53%</td>
</tr>
<tr>
<td>암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>-3.33%</td>
<td>8.54%</td>
<td>4.23%</td>
</tr>
<tr>
<td>존슨앤드본슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>-1.51%</td>
<td>3.24%</td>
<td>-0.07%</td>
</tr>
</tbody>
</table>
</figure>
왜 중요한가: 90일간의 상호 관세 유예에도 불구하고 10%의 글로벌 기본 관세와 125%의 중국 관세, 그리고 철강 및 알루미늄, 자동차, 자동차 부품에 대한 25%의 부문별 관세는 그대로 유지된다. 여기에 더해 트럼프 대통령은 곧 제약사에 대한 관세를 발표할 수 있음을 시사했다.
영향을 받을 수 있는 제약 산업 관련 상장지수펀드는 다음과 같다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>제약 ETF</td>
<td>2025년 변동</td>
<td>지난 1년 변동</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-7.02%</td>
<td>-7.51%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-7.04%</td>
<td>-6.08%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-10.13%</td>
<td>-4.37%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-14.05%</td>
<td>-11.45%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>2.88%</td>
<td>0.35%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-11.54%</td>
<td>-10.18%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-41.35%</td>
<td>-43.86%</td>
</tr>
</tbody>
</table>
</figure>
가격 움직임: 목요일 하락 후 수요일 반등에 이어 나스닥 100 지수는 전고점인 22,222.61포인트보다 17.46% 하락했다. S&amp;P 500 지수는 전고점인 6,147.43포인트 대비 14.31% 하락했고, 다우존스 지수는 52주 최고치인 45,073.63포인트 대비 12.16% 하락했다.
각각 S&amp;P 500 지수와 나스닥 100 지수를 추종하는 SPDR S&amp;P 500 ETF 신탁(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)과 인베스코 QQQ 신탁 ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 목요일에 하락 마감했다. SPY는 524.58달러로 4.38% 하락했고, QQQ는 446.18달러로 4.25% 하락했다.
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

도널드 트럼프 대통령은 화요일(8일) <a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noopener">외국 의약품</a>에 대한 "주요 관세" 계획을 공개했다.
트럼프 대통령은 <a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market" target="_blank" rel="noopener">전국공화당의회위원회(NRCC) 만찬</a>에서 이렇게 말했다. "우리는 곧 의약품에 대한 주요 관세를 발표할 것이다&#8230;관세 소식을 들으면 회사들은 중국을 떠날 것이다&#8230;대부분 제품이 미국에서 판매되기 때문이다.&#8221;
또한 트럼프는 에어포스원 기내에서 기자들에게 "제약" 관세가 "이전에는 실제로 보지 못했던 수준"에 도달할 것이라며 "가까운 장래에 발표될 것"이라고 말했다고 <a href="https://www.bbc.com/news/articles/cedyylj1v32o" target="_blank" rel="noopener">BBC는 덧붙였다.</a>
트럼프 대통령은 지난주 관세를 발표하면서 의약품을 새로운 관세 대상에서 제외했는데, 이는 <a href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" target="_blank" rel="noopener">의약품 수입</a>에 25% 관세를 부과하겠다는 이전 발언 이후 압박을 받던 업계에 안도감을 안겨준 것으로 보인다.
수요일(9일) 트럼프 대통령은 깜짝 발표를 통해 <a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noopener">미국의 무역 조치</a>에 보복하지 않은 국가에 대해 90일 동안 관세를 유예한다고 발표했다. 이 소식은 광범위한 리스크온 랠리에 불을 붙였고, 주요 지수는 수개월 만에 최고치를 기록하고 변동성이 급락했다.
트럼프는 최근 트루스 소셜에 올린 글에서 중국이 "존중이 부족하다"고 비난하며 중국산 제품에 대한 즉각적인 125% 관세 인상을 선언했다.
그는 "가까운 시일 내에 중국이 미국과 다른 국가를 상대로 폭리를 취하는 것이 더 이상 지속 가능하지도, 용납될 수도 없다는 것을 깨닫게 되기를 바란다"고 말했다. 그리고 "나의 강력한 제안에도 불구하고 어떤 방식, 형태, 형태로든 보복을 하지 않은" 75개 이상의 국가들을 칭찬했다.
이에 대한 보상으로 이들 국가는 일시적 10% 상호관세와 90일간 추가 관세 유예로부터 혜택을 받게 될 것이다.
바이오제약 산업은 트럼프 대통령의 첫 임기 동안을 포함하여 역사적으로 관세로부터 보호받아왔다.
트럼프 대통령은 자세한 내용을 밝히지 않았지만, 그의 발언은 특히 인도산 의약품에 의존하는 구매자들을 불안하게 만들었다. 인도는 미국에서 사용되는 모든 제네릭 의약품의 거의 절반을 공급하여 수십억 달러의 의료 비용을 절감하는 데 기여하고 있다.
미국은 인도의 연간 의약품 수출액 130억 달러 중 약 3분의 1을 구매하는 주요 시장이다. 인도 제약 회사들은 관세가 추가되면 가격을 인상해야 하며, 이로 인해 미국 내 의료 비용이 증가할 수 있다고 경고한다.
시플라(Cipla)와 닥터 레디스 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) 같은 일부 회사는 미국에 공장을 가지고 있지만, 대부분은 수익성이 낮은 제네릭 의약품을 생산하기에는 비용이 너무 많이 든다고 말한다.
뱅크오브아메리카 증권 애널리스트는 트럼프 행정부가 제약 산업에 관세를 부과할 계획이라면 1962년 무역확장법에 따른 &#8216;섹션 232조 조사&#8217;를 통해 특정 상품 수입이 국가 안보를 위협하는지 여부를 결정할 가능성이 높다고 말했다.
232조 조사의 일반적인 일정은 약 1년이다. 여기에 동일한 일정이 적용된다면 의약품 수입에 대한 관세는 빠르면 올해 말에나 발효될 가능성이 높다. 제약 산업에 대한 232조 조사가 곧 시작될지는 확실하지 않지만, 최근 행정부의 발언을 보면 가능성이 있는 것으로 보인다. 하지만 조사를 시작한다고 해서 반드시 관세가 부과된다는 보장은 없다.
애널리스트 팀 앤더슨(Tim Anderson)은 2025년 1분기 실적 시즌이 곧 시작되므로 기업들이 실적 발표에서 잠재적 관세에 대해 논의할지 여부를 지켜볼 필요가 있다고 말한다.
즉, 실제 수익에 미치는 영향은 2025년 이후가 되어야 나타날 가능성이 높기 때문에 투자자들은 답변보다 더 많은 질문을 남길 수 있다.
웨드부시 애널리스트 댄 아이브스는 화요일에 "미국에서 그냥 만들 수 있다고 말하는 것은 아시아의 공급망이 실제로 얼마나 복잡한지, 그리고 지난 30년 동안 미국 소비자를 위해 전자, 칩, 반도체, 하드웨어 및 스마트폰이 어떻게 구축되어 왔는지를 과소평가하는 것"이라고 <a href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst">썼다</a>.
주요 제약 회사의 주가, 예를 들어 길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), 머크 앤 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), 아스트라제네카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), 로슈 홀딩스(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), 사노피(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), 노바티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), 아겐스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>), UCB SA(OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>), 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), 리제네론(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), GSK(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) 및 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)는 수요일에 하락했다가 90일 관세 유예 발표 후 반등했다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%8A%B8%EB%9F%BC%ED%94%84%EC%9D%98-%EA%B9%9C%EC%A7%9D-%EA%B4%80%EC%84%B8-%EC%9C%A0%EC%98%88-%EA%B3%A8%EB%93%9C%EB%A7%8C%EC%82%AD%EC%8A%A4%EB%8A%94-%EA%B2%BD%EA%B8%B0%EC%B9%A8%EC%B2%B4-%EC%A0%84/">트럼프의 깜짝 관세 유예, 골드만삭스는 경기침체 전망 철회…美 증시 2008년 이후 일일 최대 상승</a>
사진 출처: MargJohnsonVA via Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주가는 씨티그룹이 주식을 <a href="https://www.benzinga.com/quote/smmt/analyst-ratings" target="_blank" rel="noreferrer noopener">매수에서 중립으로 하향 조정</a>했으나 목표 주가를 19달러에서 23달러로 상향 조정한 후 14.37% 하락했다.
2. 메이크마이트립(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>)의 주식은 12.46% 급락했다.
3. 메드페이스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>)의 주식은 제프리스(Jefferies)가 주식을 매수에서 보유로 하향 조정하고 <a href="https://www.benzinga.com/quote/medp/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 415달러에서 345달러로 하향 조정</a>한 후 9.37% 하락했다.
4. 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)의 주식은 리링크 파트너스(Leerink Partners)가 주식을 아웃퍼폼에서 시장 수익률로 <a href="https://www.benzinga.com/quote/regn/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">하향 조정</a>하고 목표 주가를 1,175달러에서 1,077달러로 하향 조정한 후 8.94% 하락했다.
5. 글로벌 페이먼츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)의 주가는 회사가 <a href="https://www.benzinga.com/pressreleases/24/09/b41024786/global-payments-shares-updated-strategy-and-medium-term-outlook-at-investor-conference" target="_blank" rel="noreferrer noopener">2025 회계연도 주당순이익(EPS) 성장률을 예상치 이하로 안내</a>한 후 여러 회사가 주식을 하향 조정하고 <a href="https://www.benzinga.com/quote/gpn/analyst-ratings" target="_blank" rel="noreferrer noopener">각각의 목표 주가를 하향 조정</a>한 후 8.74% 하락했다.
6. 어펌 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)의 주식은 회사에 특별한 뉴스가 없었음에도 불구하고 8.39% 하락했다.
7. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 회사가 8월에 <a href="https://www.benzinga.com//node/41052423" target="_blank" rel="noreferrer noopener">힌덴버그 리서치</a>의 공매도 보고서에 따라 법무부의 조사를 받고 있다는 보도가 나온 후 8.21% 하락했다.
8. 테크닙FMC(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>)의 주식은 사우디아라비아가 원유 생산량을 증가시킬 수 있다는 보도에 따라 6.10% 하락했다.
9. 퍼스트 시티즌스 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>)의 주식은 웨드부시(Wedbush)의 애널리스트가 주식을 아웃퍼폼에서 중립으로 <a href="https://www.benzinga.com/quote/fcnca/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">하향 조정</a>하고 목표 주가를 2,450달러에서 2,150달러로 하향 조정한 후 6.09% 하락했다.
10. 서비스나우(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)의 주식은 법무부의 카라소프트(Carahsoft) 조사 압박으로 인해 5.93% 하락했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A4%91%EA%B5%AD-%EC%A3%BC%EC%8B%9D-%EC%9A%B0%EC%84%B8-jd%EB%8B%B7%EC%BB%B4%EA%B3%BC-pdd%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">중국 주식이 주도 &#8211; JD닷컴과 PDD가 지난주 대형주 상승 10위 안에 포함 (9월 23일 &#8211; 9월 27일)</a></li>
</ul>
사진 제공: 회사
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

AFRM

FCNCA

KNTK

MEDP

MMYT

SMCI

SMMT

리제네론과 슈퍼 마이크로는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 23일-9월 27일)

피브로젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>)의 주가는 회사가 미국 식품의약국(FDA)이 FG-3165에 대한 임상시험용 신약(IND)을 승인했다고 발표한 후 월요일 시간외 세션에서 급등했다. 이 회사는 또한 리제네론(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/regn" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for REGN">REGN</a>)과 새로운 <a href="https://www.benzinga.com/pressreleases/24/06/g39145782/fibrogen-announces-clinical-trial-supply-agreement-with-regeneron-pharmaceuticals-to-evaluate-fibr">임상시험 공급 계약</a>을 발표했다.
사건의 전말 (What Happened): 피브로젠은 월요일 시장 마감 후 FDA가 FG-3165의 <a href="https://www.benzinga.com/pressreleases/24/06/g39145655/fibrogen-announces-fda-clearance-of-investigational-new-drug-application-for-fg-3165-a-galectin-9-">IND를 승인</a>하여 회사가 1상 임상 시험을 시작할 수 있게 되었다고 말했다.
FG-3165는 높은 Gal9 발현 수준을 특징으로 하는 고형 종양 치료를 위해 개발 중인 갈렉틴(galectin)-9 표적 단클론 항체이다. 특정 고형 종양 환자를 대상으로 FG-3165의 안전성과 효능을 평가하는 1상 시험은 2024년 하반기에 등록이 시작될 것으로 예상된다.
"현재까지 FG-3165는 마우스 암 모델에서 다른 면역 조절 치료법과 병용하여 생존율을 향상시키는 항종양 활성을 입증했으며 비임상 안전성 연구에서 우수한 내약성을 보여주었다"고 피브로젠의 CEO인 테인 웨티그(Thane Wettig)가 말했다.
피브로젠은 또한 고형 종양 환자를 대상으로 리제네론의 항PD-1 치료제 LIBTAYO(세미플리맙)와 함께 피브로젠의 면역항암제 자산인 FG-3165 및 FG-3175를 평가하기 위해 리제네론 파마슈티컬스와 임상 시험 공급 계약을 발표했다.
피브로젠은 각 1상 단독요법 및 병용 임상시험의 후원자가 될 것이다. 리제네론은 피브로젠에 약물 공급을 제공할 예정이다. 각 회사는 해당 화합물에 대한 모든 권리를 보유한다.
"우리는 FG-3165(항-Gal9)와 FG-3175(항-CCR8) 모두에 대한 작용 메커니즘이 세미플리맙과 시너지 효과를 발휘하여 환자의 임상 결과를 개선할 가능성을 제공할 수 있다고 믿는다. 리제네론과 협력 관계를 구축할 수 있기를 기대한다"고 피브로젠의 최고 의료책임자인 데야 아디브(Deyaa Adib)가 말했다.
FGEN 주가 움직임: <a href="http://pro.benzinga.com">벤징가 프로</a>에 의하면, 피브로젠의 주식은 월요일 시간외 거에서 26.85% 상승한 1.56달러에 거래되었다.
사진: Pixabay의 3844328.

Comments

Regeneron Pharmaceuticals

뉴스

에 대한 최신 뉴스 Regeneron Pharmaceuticals (NASDAQ:REGN) 주식

금요일, 4월 11, 2025

목요일, 4월 10, 2025

월요일, 12월 23, 2024

월요일, 9월 30, 2024

월요일, 6월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌